Cart
sales@molnova.com
Furegrelate sodium
CAS No. 85666-17-7
Furegrelate sodium( U-63557A )
Catalog No. M26221 CAS No. 85666-17-7
Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 46 | In Stock |
|
| 25MG | 105 | In Stock |
|
| 50MG | 198 | In Stock |
|
| 100MG | 317 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFuregrelate sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionFuregelate sodium is a selective thromboxane synthase inhibitor with oral activity.
-
DescriptionFuregelate sodium is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM.(In Vivo):Furegrelate sodium has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs) and reportedly is highly specific for its target enzyme. Furegrelate sodium (1-5 mg/kg; oral) prevents blockage of the coronary artery. Furegrelate sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused by platelet aggregation. Furegrelate sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.
-
In Vitro——
-
In VivoAnimal Model:Mongrel dogs (19-30 kg)Dosage:1-5 mg/kg Administration:Oral (via a gastric tube)Result:Prevented blockage of the coronary artery.
-
SynonymsU-63557A
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorB-Raf (V600E)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number85666-17-7
-
Formula Weight275.239
-
Molecular FormulaC15H10NNaO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 13 mg/mL (47.23 mM)
-
SMILES[Na]OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Andrew P. CrewKeith R. Hornberger, et al. Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides. WO2020051564A1
molnova catalog
related products
-
Elafibranor
A nove, potent dual PPAR α/δ agonist with EC50 of 45 and 175 nM, respectively.
-
MSDC-0602K
MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM.
-
Tetradecylthioacetic...
Tetradecylthioacetic acid is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for PPARα.
